Q-omics provides the consensus-scored HSD3BP2 profile across patient tissues and cancer cell-line models. HSD3BP2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, HSD3BP2 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, HSD3BP2 RNA expression shows 11,371 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRP, and GBM as cancer lineages where HSD3BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD3BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD3BP2 survival associations across molecular data types. HSD3BP2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD3BP2 RNA expression–survival associations across cancer types. High HSD3BP2 expression shows unfavorable associations in UVM, THCA, ACC, CESC and LUSC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify BLCA as the clearest survival context for HSD3BP2 RNA expression.
This table summarizes HSD3BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for HSD3BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD3BP2 shows lower tumor expression in KIRP, COAD, BRCA, CHOL and KICH and higher tumor expression in KIRC. The KIRP box plot shows higher HSD3BP2 RNA expression in normal versus tumor tissue (log2 FC = −0.172, t-test p < 0.001).
This table shows molecular features associated with HSD3BP2 in patient tissues and cancer cell lines. In patient samples, HSD3BP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
